ELAN — Elanco Animal Health Incorporated

Elanco Animal Health Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $1.14 billion, up 12% year-over-year; organic constant currency growth of 9%.
• Full Year Revenue: $4.715 billion, representing 6% growth.
• Adjusted EBITDA: $189 million for Q4, a 7% increase; full year adjusted EBITDA of $901 million.
• Adjusted EPS: $0.13 for Q4 (down 7% year-over-year); full year adjusted EPS of $0.94, up from $0.91 in 2024.
• Gross Margin: Adjusted gross margin at 51.2% for Q4, with full year gross margin flat at 54.9%.
• Net Debt: Approximately $3.2 billion with a net leverage ratio of 3.6x, improved from previous years.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong performance in U.S. farm animal (up 17%) and U.S. pet health (up 10%). Innovation revenue reached $892 million in 2025, with expectations to grow to $1.15 billion in 2026.
• Product Launches: Successful launches of Credelio Quattro and Zenrelia, with Quattro gaining significant market share in the U.S. and international markets.
• Acquisition: Elanco announced the acquisition of AHP International, enhancing its portfolio in the dairy sector.
• Operational Efficiency: The Elanco Ascend initiative is expected to drive cost savings and margin improvements.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • Organic constant currency revenue growth of 4% to 6%.
  • Adjusted EBITDA forecast of $955 million to $985 million (8% growth at midpoint).
  • Adjusted EPS expected between $1.00 and $1.06 (10% growth at midpoint).
• First Quarter Guidance: Revenue of $1.28 billion to $1.305 billion, with similar growth expectations across pet and farm segments.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressure: Despite innovation growth, gross margins were flat due to inflationary pressures and higher inventory costs.
• Competitive Pressures: Concerns about the impact of generics and competitive entrants in the market, particularly in the parasiticide segment.
• Market Dynamics: The company is navigating a dynamic macro environment with ongoing inflation and potential impacts from distributor mergers in the industry.

5. Notable Q&A Insights

• Zenrelia's International Gains: The product is gaining significant market share internationally, with strong efficacy driving adoption. The potential for a favorable label update in the U.S. is anticipated.
• Pricing Strategy: Elanco expects to see an acceleration in pricing in 2026, moving from 2% in 2025, reflecting the value of new innovations.
• Corporate Accounts: Elanco is making progress in securing corporate accounts, with a focus on expanding its portfolio to enhance competitiveness.
• Stock Dynamics: No significant destocking observed; distributors are actively ordering multiple times per quarter, indicating strong demand.

Overall, Elanco demonstrated strong performance in 2025, with a positive outlook for 2026, although it faces challenges from competitive pressures and margin constraints. The company remains focused on innovation and operational efficiency to drive future growth.